VIATRIS INC. Accretion Expense
VIATRIS INC. (VTRS) reported Accretion Expense of $1.80 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AccretionExpense · last filed 2026-08-06
- VIATRIS INC. accretion expense for the quarter ending 2026-06-30 was $900.00K, a 25.00% decline year-over-year.
- VIATRIS INC. accretion expense for the quarter ending 2026-03-31 was $900.00K, a 25.00% decline year-over-year.
- VIATRIS INC. accretion expense for the quarter ending 2025-12-31 was $1.10M, a 15.38% decline year-over-year.
- VIATRIS INC. accretion expense for the quarter ending 2025-09-30 was $1.00M, a 91.30% decline year-over-year.
- VIATRIS INC. accretion expense for fiscal 2025 was $4.50M, a 88.22% decline from fiscal 2024.
- VIATRIS INC. accretion expense for fiscal 2024 was $38.20M, a 68.28% increase from fiscal 2023.
- VIATRIS INC. accretion expense for fiscal 2023 was $22.70M, a 176.83% increase from fiscal 2022.
- VIATRIS INC. accretion expense for fiscal 2022 was $8.20M, a 8.89% decline from fiscal 2021.
| Period end | Accretion Expense 3 month | Accretion Expense 6 month | Accretion Expense 9 month | Accretion Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $900.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.80M 10-Q · filed 2026-08-06 | $2.90M derived: sum of 3 quarters · filed 2026-08-06 | $3.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $900.00K 10-Q · filed 2026-05-07 | $2.00M derived: sum of 2 quarters · filed 2026-05-07 | $3.00M derived: sum of 3 quarters · filed 2026-05-07 | $4.20M derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.10M derived: sum of 2 quarters · filed 2026-02-26 | $3.30M derived: sum of 3 quarters · filed 2026-02-26 | $4.50M 10-K · filed 2026-02-26 |
| 2025-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.20M derived: sum of 2 quarters · filed 2025-11-06 | $3.40M 10-Q · filed 2025-11-06 | $4.70M derived: sum of 4 quarters · filed 2026-02-26 |
| 2025-06-30 | $1.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $2.40M 10-Q · filed 2025-08-07 | $3.70M derived: sum of 3 quarters · filed 2026-02-26 | $15.20M derived: sum of 4 quarters · filed 2026-02-26 |
| 2025-03-31 | $1.20M 10-Q · filed 2025-05-08 | $2.50M derived: sum of 2 quarters · filed 2026-02-26 | $14.00M derived: sum of 3 quarters · filed 2026-02-26 | $23.50M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $12.80M derived: sum of 2 quarters · filed 2026-02-26 | $22.30M derived: sum of 3 quarters · filed 2026-02-26 | $38.20M 10-K · filed 2026-02-26 |
| 2024-09-30 | $11.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $21.00M derived: sum of 2 quarters · filed 2024-11-07 | $36.90M 10-Q · filed 2024-11-07 | $42.50M derived: sum of 4 quarters · filed 2025-02-27 |
| 2024-06-30 | $9.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $25.40M 10-Q · filed 2024-08-08 | $31.00M derived: sum of 3 quarters · filed 2025-02-27 | $36.60M derived: sum of 4 quarters · filed 2025-02-27 |
| 2024-03-31 | $15.90M 10-Q · filed 2024-05-09 | $21.50M derived: sum of 2 quarters · filed 2025-02-27 | $27.10M derived: sum of 3 quarters · filed 2025-02-27 | $32.90M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-12-31 | $5.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $11.20M derived: sum of 2 quarters · filed 2025-02-27 | $17.00M derived: sum of 3 quarters · filed 2025-02-27 | $22.70M 10-K · filed 2025-02-27 |
| 2023-09-30 | $5.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $11.40M derived: sum of 2 quarters · filed 2023-11-08 | $17.10M 10-Q · filed 2023-11-08 | $19.90M derived: sum of 4 quarters · filed 2024-02-28 |
| 2023-06-30 | $5.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $11.50M 10-Q · filed 2023-08-07 | $14.30M derived: sum of 3 quarters · filed 2024-02-28 | $16.00M derived: sum of 4 quarters · filed 2024-02-28 |
| 2023-03-31 | $5.70M 10-Q · filed 2023-05-08 | $8.50M derived: sum of 2 quarters · filed 2024-02-28 | $10.20M derived: sum of 3 quarters · filed 2024-02-28 | $12.00M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-12-31 | $2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $4.50M derived: sum of 2 quarters · filed 2024-02-28 | $6.30M derived: sum of 3 quarters · filed 2024-02-28 | $8.20M 10-K · filed 2024-02-28 |
| 2022-09-30 | $1.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $3.50M derived: sum of 2 quarters · filed 2022-11-07 | $5.40M 10-Q · filed 2022-11-07 | $7.40M derived: sum of 4 quarters · filed 2023-02-27 |
| 2022-06-30 | $1.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $3.70M 10-Q · filed 2022-08-08 | $5.70M derived: sum of 3 quarters · filed 2023-02-27 | $7.90M derived: sum of 4 quarters · filed 2023-02-27 |
| 2022-03-31 | $1.90M 10-Q · filed 2022-05-09 | $3.90M derived: sum of 2 quarters · filed 2023-02-27 | $6.10M derived: sum of 3 quarters · filed 2023-02-27 | $8.50M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $4.20M derived: sum of 2 quarters · filed 2023-02-27 | $6.60M derived: sum of 3 quarters · filed 2023-02-27 | $9.00M 10-K · filed 2023-02-27 |
| 2021-09-30 | $2.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $4.60M derived: sum of 2 quarters · filed 2021-11-08 | $7.00M 10-Q · filed 2021-11-08 | |
| 2021-06-30 | $2.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $4.80M 10-Q · filed 2021-08-09 | ||
| 2021-03-31 | $2.40M 10-Q · filed 2021-05-10 | |||
| 2020-12-31 | $11.60M 10-K · filed 2022-02-28 | |||
| 2019-12-31 | $14.80M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |